AI Services Companies

Agilisium review

Agilisium is a Los Angeles data and AI services firm, biotech, and medtech companies.

Reviewed November 13, 2026

Our verdict

Agilisium is a good fit for a pharma, biotech, or medtech company that wants a data and AI partner that works only in life sciences, from clinical operations to commercial analytics, and can place domain-trained engineers inside its teams. Buyers outside life sciences should look elsewhere.

The right buyer

  • Pharma and biotech companies putting AI agents into clinical, regulatory, and commercial work.
  • Life sciences firms that need data platforms on Databricks, Snowflake, AWS, or Salesforce built by people who know the field.

Reasons to look elsewhere

  • Companies outside life sciences.
  • Buyers who want a large firm with decades of named public case studies.

Agilisium, At A High Level

Raj Babu founded Agilisium in 2014 as a data and analytics consultancy and turned it toward life sciences in 2018; since then the firm says that segment has grown about 45% a year. It has around 1,400 people, most of them in Chennai, Hyderabad, and Pune in India, with sites in Canada and Costa Rica and US clients in Massachusetts, New Jersey, Pennsylvania, California, and Illinois. It expects revenue of $72 million to $75 million in 2026, according to Business Standard.

The firm describes itself as a context-centric AI company for life sciences. It sells AI agents for clinical trials, regulatory intelligence, MLR review, value dossiers, co-pay analytics, and launch planning, and in March 2026 it put $5.5 million into FDX, a program that trains people with backgrounds in biology, pharmacology, and medicine as forward deployment experts who work inside client teams. It builds on Claude from Anthropic, AWS, Databricks, Snowflake, Salesforce, and Veeva.

Scores by criterion

CriterionWeightScoreBasis
Production track record20%7.0A decade of data work; life sciences focus since 2018.
Technical depth15%7.0Data platforms, AI agents, and Claude-based builds.
Industry depth10%8.5Works only in pharma, biotech, and medtech.
Delivery model and handoff15%7.0Forward deployment experts and managed teams that stay after launch.
Commercial clarity10%5.5No public pricing or rate card.
Platform independence10%6.5Builds on Anthropic, AWS, Databricks, Snowflake, Salesforce, and Veeva.
Stability and scale10%7.0About 1,400 people; 2026 revenue of $72M to $75M.
Independent evidence10%6.0Press coverage and company releases; few named public case studies.
Overall100%6.9Weighted average

Where Agilisium fits

Agilisium sells to pharma, biotech, and medtech companies that want data platforms and AI agents built and run by people who know clinical, regulatory, and commercial work. It is best for clinical trial and regulatory AI agents, commercial analytics such as launch planning and co-pay analysis, and Databricks, Snowflake, and Salesforce data work in life sciences. On price it sits with offshore-delivered analytics and AI firms, below the large life sciences consultancies.

Its closest substitutes for the same work: ZS for large life sciences analytics and AI consulting; Atorus Research for clinical data and statistical programming; Tredence for data science and AI with life sciences clients; Sigmoid for data engineering and AI with pharma clients.

What clients and leaders say

“The next opportunity is to combine this strength with scientific expertise, deep industry knowledge and proprietary IP to transform global industries.”

Raj Babu, founder and CEO, Agilisium (Business Standard, October 27, 2026) · Source

“Their consultants understood our trial protocols, so the agent work started from the right questions.”

“Most of the team sits in India, so live working hours with our Boston group were short.”

Where customer reviews couldn’t be found, our analysts attempted to give a voice to buyer sentiment, drawing on real information from review sites, forums and product documentation. Based on: Agilisium homepage, DT Next on Agilisium hiring and growth.

Who leads Agilisium

Sources (6)
  1. Agilisium homepage (services, agents, partners)
  2. Agilisium leadership
  3. Business Standard: Agilisium shifts Asia HQ to Hyderabad (October 27, 2026)
  4. DT Next: Agilisium targets $500 mn revenue (October 12, 2026)
  5. Agilisium invests $5.5 million in FDX (March 19, 2026)
  6. Agilisium on LinkedIn